Folliculotropic mycosis fungoides responding to bexarotene gel

Hobart W. Walling*, Brian L. Swick, Pedram Gerami, Richard K. Scupham

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FMF. The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.

Original languageEnglish (US)
Pages (from-to)169-171
Number of pages3
JournalJournal of Drugs in Dermatology
Volume7
Issue number2
StatePublished - Feb 1 2008

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Folliculotropic mycosis fungoides responding to bexarotene gel'. Together they form a unique fingerprint.

Cite this